Clinical Trials Logo

Clinical Trial Summary

This pilot clinical trial studies magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy (SBRT) in treating patients with liver metastases or liver cancer. SBRT is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Combining MRI with SBRT may help doctors to highlight the tissues surrounding the tumor better.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To assess the feasibility of utilizing an MRI-guided tri-60Co teletherapy system for liver SBRT, as determined the treating radiation oncologist's ability to accurately visualize and align to the target lesion(s). II. To assess the feasibility of using a three versus five fraction scheme, for one versus multiple (i.e., =< 5) target lesions. SECONDARY OBJECTIVES: I. To determine the tumor local control (LC), disease specific survival (DSS), and overall survival (OS). II. To gather biomarkers that may elucidate differential immunogenic responses from the three versus the five fraction SBRT regimens. OUTLINE: Patients undergo MRI-guided Tri-60Co teletherapy SBRT 3-5 fractions over 1-2 weeks. After completion of study treatment, patients are followed up at approximately 4-6 weeks, and then every 3 months for 2 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02683200
Study type Interventional
Source Jonsson Comprehensive Cancer Center
Contact
Status Completed
Phase Early Phase 1
Start date June 3, 2015
Completion date January 1, 2022

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03068624 - Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma Phase 1
Recruiting NCT04728633 - Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases Phase 2
Recruiting NCT05863195 - Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial Phase 3
Active, not recruiting NCT02156739 - Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions N/A
Recruiting NCT05039632 - Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies Phase 1/Phase 2
Recruiting NCT05040360 - Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors Phase 2
Active, not recruiting NCT02738606 - Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery Phase 2
Active, not recruiting NCT03472586 - Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver Phase 2
Recruiting NCT05791448 - AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease Phase 1
Completed NCT00862680 - 4D PET/CT in Diagnosing Participants With Lung and Colorectal Cancer With Liver and Lung Metastasis
Active, not recruiting NCT02070549 - Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction Phase 1
Recruiting NCT03203525 - Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer Phase 1
Recruiting NCT03844750 - Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases Phase 2
Recruiting NCT04982653 - Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy Phase 2
Active, not recruiting NCT02626312 - Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function Phase 1
Active, not recruiting NCT02364557 - Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival Phase 2/Phase 3
Active, not recruiting NCT03457948 - Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases Phase 2
Recruiting NCT04796818 - An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response N/A
Recruiting NCT06016855 - Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors Phase 4